RAPT

RAPT

USD

RAPT Therapeutics Inc. Common Stock

$28.500-0.050 (-0.175%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$28.550

Máximo

$29.605

Mínimo

$28.190

Volume

0.43M

Fundamentos da empresa

Capitalização de mercado

708.8M

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

0.36M

Bolsa de valores

NGM

Moeda

USD

Faixa de 52 semanas

Mínimo $5.664Atual $28.500Máximo $42.392

Notícias relacionadas

GlobeNewswire

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing

Ver mais
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
Analyst Upgrades

Wells Fargo Maintains Overweight on RAPT Therapeutics, Raises Price Target to $72

Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics with a Overweight and raises the price target from $48 to $72.

Ver mais
Wells Fargo Maintains Overweight on RAPT Therapeutics, Raises Price Target to $72
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on RAPT Therapeutics, Raises Price Target to $72

HC Wainwright & Co. analyst Emily Bodnar maintains RAPT Therapeutics with a Buy and raises the price target from $27 to $72.

Ver mais
HC Wainwright & Co. Maintains Buy on RAPT Therapeutics, Raises Price Target to $72
Analyst Upgrades

Guggenheim Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $70

Guggenheim analyst Yatin Suneja initiates coverage on RAPT Therapeutics with a Buy rating and announces Price Target of $70.

Ver mais
Guggenheim Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $70
GlobeNewswire

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and

Ver mais
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
Analyst Upgrades

Wells Fargo Maintains Overweight on RAPT Therapeutics, Raises Price Target to $48

Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics with a Overweight and raises the price target from $38 to $48.

Analyst Upgrades

Barclays Maintains Overweight on RAPT Therapeutics, Raises Price Target to $58

Barclays analyst Etzer Darout maintains RAPT Therapeutics with a Overweight and raises the price target from $35 to $58.